Subject(s)
Infectious Disease Transmission, Patient-to-Professional/prevention & control , Inhalation Exposure/prevention & control , Masks/supply & distribution , Occupational Exposure/prevention & control , Occupational Health , Respiratory Protective Devices/supply & distribution , Respiratory Tract Infections/therapy , Aerosols , Humans , Inhalation Exposure/adverse effects , Occupational Exposure/adverse effects , Particle Size , Respiratory Tract Infections/transmission , Respiratory Tract Infections/virology , Risk Assessment , Risk FactorsABSTRACT
A meta-analysis was performed to assess randomized controlled trials comparing local endovascular therapy (with and without intravenous thrombolysis) versus standard care (intravenous thrombolysis alone when appropriate) for acute ischemic stroke. Local endovascular therapy showed a significant improvement in functional independence versus standard care (odds ratio, 1.779; 95% confidence interval, 1.262-2.507; P < .001). This benefit strengthened further on subgroup analyses of trials in which a majority of cases used stent retrievers, trials with intravenous thrombolysis use in both arms when appropriate, and trials that required preprocedural imaging of all patients. There were no significant differences between arms in terms of mortality, hemicraniectomy, intracranial hemorrhage, and cerebral edema rates (P > .05). In conclusion, in the treatment of acute ischemic stroke, local endovascular therapy leads to improved functional independence compared with standard care.
Subject(s)
Brain Ischemia/therapy , Endovascular Procedures , Fibrinolytic Agents/administration & dosage , Stroke/therapy , Thrombolytic Therapy , Administration, Intravenous , Brain Ischemia/diagnosis , Brain Ischemia/mortality , Brain Ischemia/physiopathology , Cerebrovascular Circulation , Disability Evaluation , Endovascular Procedures/adverse effects , Endovascular Procedures/mortality , Fibrinolytic Agents/adverse effects , Humans , Odds Ratio , Randomized Controlled Trials as Topic , Recovery of Function , Risk Factors , Stroke/diagnosis , Stroke/mortality , Stroke/physiopathology , Thrombolytic Therapy/adverse effects , Thrombolytic Therapy/mortality , Treatment OutcomeABSTRACT
PURPOSE: To perform a meta-analysis of randomized controlled trials (RCTs) of drug-eluting balloon (DEB) angioplasty and drug-eluting stents (DESs) for infrainguinal peripheral arterial disease. MATERIALS AND METHODS: Systematic searches were performed for all relevant RCTs. RESULTS: Eight RCTs for DEB angioplasty and 12 RCTs for a DES in peripheral arterial disease were identified. Meta-analysis demonstrated statistically significant superiority of DEB over plain balloon angioplasty of femoral-popliteal disease for late lumen loss, restenosis, and target lesion revascularization, with no benefit in major amputation or mortality. Statistically significant superiority of DEB over percutaneous transluminal angioplasty (PTA) was demonstrated for infrapopliteal disease for restenosis and target lesion revascularization. Drug-eluting stents showed statistically significant superiority over bare metal stents (BMSs) of femoral-popliteal disease for late lumen loss and restenosis, with no benefit in mortality or amputation. Drug-eluting stents showed statistically significant superiority over BMSs of infrapopliteal disease restenosis and target lesion revascularization, with no benefit in amputation or mortality. CONCLUSIONS: Drug-eluting balloon angioplasty and DESs demonstrated superior outcomes compared to PTA and BMS, with no difference in amputation or mortality.
Subject(s)
Angioplasty, Balloon/mortality , Drug-Eluting Stents/statistics & numerical data , Peripheral Arterial Disease/mortality , Peripheral Arterial Disease/therapy , Aged , Angioplasty, Balloon/statistics & numerical data , Female , Femoral Artery/surgery , Humans , Incidence , Male , Middle Aged , Popliteal Artery/surgery , Randomized Controlled Trials as Topic , Risk Factors , Survival RateABSTRACT
Addition of thiosemicarbazide, 4-allylthiosemicarbazide, and 4-phenylthiosemicarbazide to (formylphenyl)boronic acids affords a series of thiosemicarbazones containing boronic acids. Addition of 2-formylphenylboronic acid to the thiosemicarbazides gave the corresponding cyclic 2,3,1-benzodiazaborines. All new compounds have been investigated for potential antifungal activity.
